title: Screening of multiple myeloma by polyclonal rabbit anti-human plasmacytoma cell immunoglobulin.
abstract: Antibody-based immunotherapy has been effectively used for tumor treatment. However, to date, only a few tumor-associated antigens (TAAs) or therapeutic targets have been identified. Identification of more immunogenic antigens is essential for improvements in multiple myeloma (MM) diagnosis and therapy. In this study, we synthesized a polyclonal antibody (PAb) by immunizing rabbits with whole human plasmacytoma ARH-77 cells and identified MM-associated antigens, including enlonase, adipophilin, and HSP90s, among others, via proteomic technologies. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay showed that 200 µg/mL PAb inhibits the proliferation of ARH-77 cells by over 50% within 48 h. Flow cytometric assay indicated that PAb treatment significantly increases the number of apoptotic cells compared with other treatments (52.1% vs. NS, 7.3% or control rabbit IgG, 9.9%). In vivo, PAb delayed tumor growth and prolonged the lifespan of mice. Terminal deoxynucleotidyl transferase dUTP nick end labeling assay showed that PAb also induces statistically significant changes in apoptosis compared with other treatments (P<0.05). We therefore conclude that PAb could be used for the effective screening and identification of TAA. PAb may have certain anti-tumor functions in vitro and in vivo. As such, its combination with proteomic technologies could be a promising approach for sieving TAA for the diagnosis and therapy of MM.
authors.affiliation: The Medical Biology Staff Room of North Sichuan Medical College, Sichuan Nanchong, PR China. ppnu2@yahoo.com.cn
authors.forename: Bo
authors.initials: B
authors.lastname: Mu
authors.forename: Huan
authors.initials: H
authors.lastname: Zhang
authors.forename: Xiaoming
authors.initials: X
authors.lastname: Cai
authors.forename: Junbao
authors.initials: J
authors.lastname: Yang
authors.forename: Yuewu
authors.initials: Y
authors.lastname: Shen
authors.forename: Baofeng
authors.initials: B
authors.lastname: Chen
authors.forename: Suhua
authors.initials: S
authors.lastname: Liang
mesh_terms: D000818:Animals; D000912:Antibodies, Neoplasm / Q000276:immunology* / Q000302:isolation & purification / Q000494:pharmacology; D000951:Antigens, Neoplasm / Q000032:analysis / Q000276:immunology*; D017209:Apoptosis / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D005260:Female; D006801:Humans; D007114:Immunization; D020287:In Situ Nick-End Labeling; D051379:Mice; D016513:Mice, SCID; D009101:Multiple Myeloma / Q000175:diagnosis* / Q000188:drug therapy / Q000276:immunology* / Q000401:mortality; D009368:Neoplasm Transplantation; D010954:Plasmacytoma / Q000276:immunology* / Q000473:pathology; D040901:Proteomics; D011817:Rabbits; D016019:Survival Analysis; D047368:Tumor Burden / Q000187:drug effects
chemical_list: D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm
references.citation: Nat Rev Cancer. 2007 Aug;7(8):585-98
references.pmid: 17646864
references.citation: Cancer Epidemiol Biomarkers Prev. 2011 Oct;20(10):2195-203
references.pmid: 21828233
references.citation: Int J Cancer. 1992 Jun 19;51(4):613-9
references.pmid: 1601523
references.citation: Genomics. 2004 Dec;84(6):1014-20
references.pmid: 15533718
references.citation: Cancer Sci. 2007 Oct;98(10):1536-9
references.pmid: 17645779
references.citation: Cancers (Basel). 2012 Feb 22;4(1):193-217
references.pmid: 24213236
references.citation: Mol Cell Biochem. 2010 Apr;337(1-2):193-9
references.pmid: 19851831
references.citation: Nat Med. 2000 Oct;6(10):1160-6
references.pmid: 11017149
references.citation: Acta Neuropathol. 2009 Oct;118(4):469-74
references.pmid: 19554337
references.citation: Oncol Rep. 2010 Apr;23(4):949-56
references.pmid: 20204278
references.citation: Bone Marrow Res. 2011;2011:924058
references.pmid: 22046572
references.citation: Future Oncol. 2010 Apr;6(4):551-62
references.pmid: 20373869
references.citation: J Immunol. 2011 Feb 1;186(3):1840-8
references.pmid: 21187443
references.citation: Leukemia. 2012 Oct;26(10):2186-96
references.pmid: 22652755
references.citation: Methods Mol Med. 2005;109:137-54
references.pmid: 15585919
references.citation: J Cell Sci. 2011 Oct 1;124(Pt 19):3247-53
references.pmid: 21878492
references.citation: Nat Struct Mol Biol. 2013 Jan;20(1):1-4
references.pmid: 23288357
references.citation: Pharmaceuticals (Basel). 2012 Sep 12;5(9):1008-20
references.pmid: 24280702
references.citation: Int J Cancer. 2006 May 1;118(9):2210-9
references.pmid: 16331622
references.citation: Blood. 2012 Jun 21;119(25):6080-8
references.pmid: 22566604
references.citation: Cell Tissue Res. 1998 Nov;294(2):309-21
references.pmid: 9799447
references.citation: Nat Cell Biol. 2004 Jun;6(6):507-14
references.pmid: 15146192
references.citation: Methods Mol Med. 2005;115:109-28
references.pmid: 15998965
references.citation: Clin Cancer Res. 2009 Nov 15;15(22):6901-11
references.pmid: 19861439
references.citation: Clin Cancer Res. 2009 Jan 1;15(1):9-14
references.pmid: 19118027
references.citation: Int J Cancer. 2010 Mar 15;126(6):1513-20
references.pmid: 19688824
references.citation: J Mammary Gland Biol Neoplasia. 1998 Jul;3(3):259-73
references.pmid: 10819513
references.citation: Future Oncol. 2009 Jun;5(5):679-88
references.pmid: 19519207
references.citation: Nat Rev Clin Oncol. 2011 Apr 26;8(8):479-91
references.pmid: 21522124
references.citation: Nat Rev Clin Oncol. 2012 Feb 21;9(3):135-43
references.pmid: 22349016
references.citation: Biochem Biophys Res Commun. 2008 Oct 24;375(3):440-5
references.pmid: 18722351
references.citation: Br J Cancer. 2009 May 19;100(10):1523-9
references.pmid: 19401686
references.citation: Cell Prolif. 1999 Dec;32(6):363-78
references.pmid: 10646688
references.citation: Leuk Lymphoma. 2010 Nov;51(11):2144-6
references.pmid: 20807088
references.citation: Mayo Clin Proc. 2010 May;85(5):410-2
references.pmid: 20435833
references.citation: Nat Biotechnol. 2005 Sep;23(9):1147-57
references.pmid: 16151408
references.citation: Int J Mol Med. 2005 Jan;15(1):137-44
references.pmid: 15583840
references.citation: Mayo Clin Proc. 2002 Aug;77(8):813-22
references.pmid: 12173715
references.citation: Trends Endocrinol Metab. 2011 Jun;22(6):211-7
references.pmid: 21592818
references.citation: Cancer Res. 2006 Sep 15;66(18):9153-61
references.pmid: 16982758
references.citation: J Biol Chem. 2009 Aug 21;284(34):22559-67
references.pmid: 19553666
references.citation: J Thorac Oncol. 2008 Jun;3(6 Suppl 2):S152-9
references.pmid: 18520302
references.citation: J Lipid Res. 2003 Apr;44(4):668-73
references.pmid: 12562852
references.citation: Cell Cycle. 2010 Jun 15;9(12):2310-6
references.pmid: 20519952
references.citation: Proteomics. 2005 Apr;5(6):1686-92
references.pmid: 15800975
references.citation: PLoS One. 2012;7(11):e49194
references.pmid: 23145121
references.citation: Anticancer Res. 2002 Jul-Aug;22(4):1933-41
references.pmid: 12174867
references.citation: Nat Rev Cancer. 2010 Aug;10(8):537-49
references.pmid: 20651736
references.citation: PLoS One. 2012;7(8):e42722
references.pmid: 22912728
references.citation: PLoS One. 2012;7(6):e37475
references.pmid: 22761656
references.citation: Recent Pat Anticancer Drug Discov. 2012 May 1;7(2):185-97
references.pmid: 22338595
references.citation: PLoS One. 2011 Apr 14;6(4):e18848
references.pmid: 21533148
references.citation: PLoS One. 2012;7(8):e44315
references.pmid: 22952953
references.citation: J Biomed Biotechnol. 2012;2012:156795
references.pmid: 23118496
references.citation: Oncogene. 2011 Aug 18;30(33):3570-84
references.pmid: 21399663
references.citation: EMBO Rep. 2009 Dec;10(12):1341-7
references.pmid: 19820692
references.citation: Oncol Rep. 2012 Nov;28(5):1903-9
references.pmid: 22941268
references.citation: Cancer Immun. 2004 Jul 16;4:5
references.pmid: 15255672
references.citation: Oncol Rep. 2011 May;25(5):1343-51
references.pmid: 21369706
references.citation: Cancer Sci. 2010 Nov;101(11):2411-6
references.pmid: 20731664